Do you have patients with high blood pressure and chronic kidney disease (CKD)?

Consider enrolling them on the BLOCK | CKD Study.

The BLOCK-CKD study is investigating the effectiveness of a new, non-steroidal mineralocorticoid receptor antagonist (MRA) for the treatment of hypertension and nephropathy, including diabetic and hypertensive nephropathy.

For more information about the BLOCK-CKD Study, please contact:

270-441-4606 (OR CALL/TEXT 270-994-9926)

FOUR RIVERS CLINICAL RESEARCH

225 MEDICAL CENTER DR., SUITE 305

PADUCAH, KY 42003

Eligibility Criteria

Study Design

Phase 2b, study to assess the efficacy, safety, and PK of KBP-5074 in patients with moderate-to-severe CKD and uncontrolled hypertension.

The study will consist of up to a 4-week screening period, 2-week open-label (placebo) run-in period, 84-day double-blind treatment period, and a 4-week post-treatment follow-up period.

KBP BIOSCIENCES